|
1
|
World Health Organization: WHO coronavirus
(COVID-19) dashboard. https://covid19.who.int/. Accessed August 28,
2022.
|
|
2
|
Naleway AL, Groom HC, Crawford PM, Salas
SB, Henninger ML, Donald JL, Smith N, Thompson MG, Blanton LH,
Bozio CH and Azziz-Baumgartner E: Incidence of SARS-CoV-2
infection, emergency department visits, and hospitalizations
because of COVID-19 among persons aged ≥12 years, by COVID-19
vaccination status-oregon and washington, July 4-September 25,
2021. MMWR Morb Mortal Wkly Rep. 70:1608–1612. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Paidas MJ, Sampath N, Schindler EA, Cosio
DS, Ndubizu CO, Shamaladevi N, Kwal J, Rodriguez S, Ahmad A, Kenyon
NS and Jayakumar AR: Mechanism of Multi-organ injury in
experimental COVID-19 and its inhibition by a small molecule
peptide. Front Pharmacol. 13(864798)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Darif D, Hammi I, Kihel A, El Idrissi Saik
I, Guessous F and Akarid K: The pro-inflammatory cytokines in
COVID-19 pathogenesis: What goes wrong? Microb Pathog.
153(104799)2021.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mogensen TH: Pathogen recognition and
inflammatory signaling in innate immune defenses. Clin Microbiol
Rev. 22:240–273. 2009.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen LYC, Hoiland RL, Stukas S, Wellington
CL and Sekhon MS: Confronting the controversy: Interleukin-6 and
the COVID-19 cytokine storm syndrome. Eur Respir J.
56(2003006)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Fraenkel L, Bathon JM, England BR, St
Clair EW, Arayssi T, Carandang K, Deane KD, Genovese M, Huston KK,
Kerr G, et al: 2021 American college of rheumatology guideline for
the treatment of rheumatoid arthritis. Arthritis Care Res
(Hoboken). 73:924–939. 2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
RECOVERY Collaborative Group. Tocilizumab
in patients admitted to hospital with COVID-19 (RECOVERY): A
randomised, controlled, open-label, platform trial. Lancet.
397:1637–1645. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
REMAP-CAP Investigators, Gordon AC,
Mouncey PR, Al-Beidh F, Rowan KM, Nichol AD, Arabi YM, Annane D,
Beane A, van Bentum-Puijk W, et al: Interleukin-6 receptor
antagonists in critically ill patients with Covid-19. N Engl J Med.
384:1491–1502. 2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Berardicurti O, Ruscitti P, Ursini F,
D'Andrea S, Ciaffi J, Meliconi R, Iagnocco A, Cipriani P and
Giacomelli R: Mortality in tocilizumab-treated patients with
COVID-19: A systematic review and meta-analysis. Clin Exp
Rheumatol. 38:1247–1254. 2020.PubMed/NCBI
|
|
11
|
Ghosn L, Chaimani A, Evrenoglou T,
Davidson M, Graña C, Schmucker C, Bollig C, Henschke N, Sguassero
Y, Nejstgaard CH, et al: Interleukin-6 blocking agents for treating
COVID-19: A living systematic review. Cochrane Database Syst Rev.
3(CD013881)2021.PubMed/NCBI View Article : Google Scholar
|
|
12
|
WHO Rapid Evidence Appraisal for COVID-19
Therapies (REACT) Working Group. Shankar-Hari M, Vale CL, Godolphin
PJ, Fisher D, Higgins JPT, Spiga F, Savovic J, Tierney J, Baron G,
et al: Association between administration of IL-6 antagonists and
mortality among patients hospitalized for COVID-19: A
meta-analysis. JAMA. 326:499–518. 2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
San-Juan R, Fernández-Ruiz M,
López-Medrano F, Carretero O, Lalueza A, Maestro de la Calle G,
Pérez-Jacoiste Asín MA, Bueno H, Caro-Teller JM, Catalán M, et al:
Analysis of the factors predicting clinical response to tocilizumab
therapy in patients with severe COVID-19. Int J Infect Dis.
117:56–64. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
World Health Organization: Therapeutics
and COVID-19. Living guideline, July 6, 2021. https://apps.who.int/iris/bitstream/handle/10665/342368/WHO-2019-nCoV-therapeutics-2021.2-eng.pdf.
Accessed August 28, 2022.
|
|
15
|
Salvarani C, Dolci G, Massari M, Merlo DF,
Cavuto S, Savoldi L, Bruzzi P, Boni F, Braglia L, Turrà C, et al:
Effect of tocilizumab vs standard care on clinical worsening in
patients hospitalized with COVID-19 pneumonia: A randomized
clinical trial. JAMA Intern Med. 181:24–31. 2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Setiawati R, Widyoningroem A, Handarini T,
Hayati F, Basja AT, Putri ARDS, Jaya MG, Andriani J, Tanadi MR and
Kamal IH: Modified chest X-Ray scoring system in evaluating
severity of COVID-19 patient in Dr. Soetomo general hospital
Surabaya, Indonesia. Int J Gen Med. 14:2407–2412. 2021.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang J, Chen C, Yang Y and Yang J:
Effectiveness of tocilizumab in the treatment of hospitalized
adults COVID-19: A systematic review and meta-analysis. Medicine
(Baltimore). 101(e28967)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Peng J, She X, Mei H, Zheng H, Fu M, Liang
G, Wang Q and Liu W: Association between tocilizumab treatment and
clinical outcomes of COVID-19 patients: A systematic review and
meta-analysis. Aging (Albany NY). 14:557–571. 2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Luo L, Luo T, Du M, Mei H and Hu Y:
Efficacy and safety of tocilizumab in hospitalized COVID-19
patients: A systematic review and meta-analysis. J Infect.
84:418–467. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Vela D, Vela-Gaxha Z, Rexhepi M, Olloni R,
Hyseni V and Nallbani R: Efficacy and safety of tocilizumab versus
standard care/placebo in patients with COVID-19; a systematic
review and meta-analysis of randomized clinical trials. Br J Clin
Pharmacol. 88:1955–1963. 2022.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Piscoya A, Parra Del Riego A,
Cerna-Viacava R, Rocco J, Roman YM, Escobedo AA, Pasupuleti V,
White CM and Hernandez AV: Efficacy and harms of tocilizumab for
the treatment of COVID-19 patients: A systematic review and
meta-analysis. PLoS One. 17(e0269368)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z,
Xiang J, Wang Y, Song B, Gu X, et al: Clinical course and risk
factors for mortality of adult inpatients with COVID-19 in Wuhan,
China: A retrospective cohort study. Lancet. 395:1054–1062.
2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kokkoris S, Gkoufa A, Maneta E, Doumas G,
Mizi E, Georgakopoulou VE, Sigala I, Dima E, Papachatzakis I,
Ntaidou TK, et al: Older adults with severe coronavirus disease
2019 admitted to intensive care unit: Prevalence, characteristics
and risk factors for mortality. Minerva Anestesiol: Apr 13, 2022
(Epub ahead of print).
|
|
24
|
Gkoufa A, Maneta E, Ntoumas GN,
Georgakopoulou VE, Mantelou A, Kokkoris S and Routsi C: Elderly
adults with COVID-19 admitted to intensive care unit: A narrative
review. World J Crit Care Med. 10:278–289. 2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zekavat SM, Lin SH, Bick AG, Liu A,
Paruchuri K, Wang C, Uddin MM, Ye Y, Yu Z, Liu X, et al:
Hematopoietic mosaic chromosomal alterations increase the risk for
diverse types of infection. Nat Med. 27:1012–1024. 2021.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Georgakopoulou VE, Papalexis P, Sanos C,
Bitsani A, Garmpi A, Damaskos C, Garmpis N, Gkoufa A, Chlapoutakis
S, Sklapani P, et al: Asymptomatic SARS-CoV-2 infection in an
unvaccinated 97-year-old woman: A case report. Biomed Rep.
15(107)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
AlQahtani H, AlBilal S, Mahmoud E,
Aldibasi O, Alharbi A, Shamas N, Alsaedy A, Owaidah K, Alqahtani
FY, Aleanizy FS, et al: Outcomes associated with tocilizumab with
or without corticosteroid versus dexamethasone for treatment of
patients with severe to critical COVID-19 pneumonia. J Infect
Public Health. 15:36–41. 2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Duarte-Millán MA, Mesa-Plaza N,
Guerrero-Santillán M, Morales-Ortega A, Bernal-Bello D,
Farfán-Sedano AI, García de Viedma-García V, Velázquez-Ríos L,
Frutos-Pérez B, De Ancos-Aracil CL, et al: Prognostic factors and
combined use of tocilizumab and corticosteroids in a Spanish cohort
of elderly COVID-19 patients. J Med Virol. 94:1540–1549.
2022.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Desai HD, Sharma K, Parikh A, Patel K,
Trivedi J, Desai R, Patel PP, Patel Z, Patel S and Kini S:
Predictors of mortality amongst tocilizumab administered COVID-19
asian indians: A predictive study from a tertiary care centre.
Cureus. 13(e13116)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Ercan S, Ergan B, Özuygur SS, Korkmaz P,
Taşbakan MS, Basoglu ÖK, Kerget B, Akgün M, Elbek O, Sayıner A and
Kılınç O: Clinical predictors of response to tocilizumab: A
retrospective multicenter study. Turk Thorac J. 23:225–230.
2022.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Sarabia De Ardanaz L, Andreu-Ubero JM,
Navidad-Fuentes M, Ferrer-González MÁ, Ruíz Del Valle V,
Salcedo-Bellido I, Barrios-Rodríguez R, Cáliz-Cáliz R and Requena
P: Tocilizumab in COVID-19: Factors associated with mortality
before and after treatment. Front Pharmacol.
12(620187)2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Pagkratis K, Chrysikos S, Antonakis E,
Pandi A, Kosti CN, Markatis E, Hillas G, Digalaki A, Koukidou S,
Chaini E, et al: Predictors of mortality in tocilizumab-treated
severe COVID-19. Vaccines (Basel). 10(978)2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Masotti L, Landini G, Panigada G, Grifoni
E, Tarquini R, Cei F, Cimolato BMA, Vannucchi V, Di Pietro M, Piani
F, et al: Predictors of poor outcome in tocilizumab treated
patients with Sars-CoV-2 related severe respiratory failure: A
multicentre real world study. Int Immunopharmacol.
107(108709)2022.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Mussini C, Cozzi-Lepri A, Menozzi M,
Meschiari M, Franceschini E, Milic J, Brugioni L, Pietrangelo A,
Girardis M, Cossarizza A, et al: Development and validation of a
prediction model for tocilizumab failure in hospitalized patients
with SARS-CoV-2 infection. PLoS One. 16(e0247275)2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Biolè C, Bianco M, Núñez-Gil IJ, Cerrato
E, Spirito A, Roubin SR, Viana-Llamas MC, Gonzalez A, Castro-Mejía
AF, Eid CM, et al: Gender differences in the presentation and
outcomes of hospitalized patients with COVID-19. J Hosp Med.
16:349–352. 2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Brook R, Lim HY, Ho P and Choy KW: Risk
factors and early prediction of clinical deterioration and
mortality in adult COVID-19 inpatients: An Australian tertiary
hospital experience. Intern Med J. 52:550–558. 2022.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Fortunato F, Martinelli D, Lo Caputo S,
Santantonio T, Dattoli V, Lopalco PL and Prato R: Sex and gender
differences in COVID-19: An Italian local register-based study. BMJ
Open. 11(e051506)2021.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Georgakopoulou VE, Garmpis N, Damaskos C,
Valsami S, Dimitroulis D, Diamantis E, Farmaki P, Papageorgiou CV,
Makrodimitri S, Gravvanis N, et al: The impact of peripheral
eosinophil counts and eosinophil to lymphocyte ratio (ELR) in the
clinical course of COVID-19 patients: A retrospective study. In
Vivo. 35:641–648. 2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Georgakopoulou VE, Lembessis P, Skarlis C,
Gkoufa A, Sipsas NV and Mavragani CP: Hematological abnormalities
in COVID-19 disease: Association with type I interferon pathway
activation and disease outcomes. Front Med (Lausanne).
9(850472)2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Georgakopoulou VE, Vlachogiannis NI,
Basoulis D, Eliadi I, Georgiopoulos G, Karamanakos G, Makrodimitri
S, Samara S, Triantafyllou M, Voutsinas PM, et al: A simple
prognostic score for critical COVID-19 derived from patients
without comorbidities performs well in unselected patients. J Clin
Med. 11(1810)2022.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Georgakopoulou VE, Makrodimitri S,
Triantafyllou M, Samara S, Voutsinas PM, Anastasopoulou A,
Papageorgiou CV, Spandidos DA, Gkoufa A, Papalexis P, et al:
Immature granulocytes: Innovative biomarker for SARS-CoV-2
infection. Mol Med Rep. 26(217)2022.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Cholongitas E, Bali T, Georgakopoulou VE,
Giannakodimos A, Gyftopoulos A, Georgilaki V, Gerogiannis D,
Basoulis D, Eliadi I, Karamanakos G, et al: Prevalence of abnormal
liver biochemistry and its impact on COVID-19 patients' outcomes: A
single-center Greek study. Ann Gastroenterol. 35:290–296.
2022.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Tom J, Bao M, Tsai L, Qamra A, Summers D,
Carrasco-Triguero M, McBride J, Rosenberger CM, Lin CJF, Stubbings
W, et al: Prognostic and predictive biomarkers in patients with
coronavirus disease 2019 treated with tocilizumab in a randomized
controlled trial. Crit Care Med. 50:398–409. 2022.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Lohse A, Klopfenstein T, Balblanc JC,
Royer PY, Bossert M, Gendrin V, Charpentier A, Bozgan AM, Badie J,
Bourgoin C, et al: Predictive factors of mortality in patients
treated with tocilizumab for acute respiratory distress syndrome
related to coronavirus disease 2019 (COVID-19). Microbes Infect.
22:500–503. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Lakatos B, Szabo BG, Bobek I, Gopcsa L,
Beko G, Kiss-Dala N, Petrik B, Gaspar Z, Farkas BF, Sinko J, et al:
Laboratory parameters predicting mortality of adult in-patients
with COVID-19 associated cytokine release syndrome treated with
high-dose tocilizumab. Acta Microbiol Immunol Hung: Aug 6, 2021
(Epub ahead of print).
|
|
46
|
Bone RC, Francis PB and Pierce AK:
Intravascular coagulation associated with the adult respiratory
distress syndrome. Am J Med. 61:585–589. 1976.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Peiris JS, Yuen KY, Osterhaus AD and Stöhr
K: The severe acute respiratory syndrome. N Engl J Med.
349:2431–2441. 2003.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Liu Y, Sun W, Guo Y, Chen L, Zhang L, Zhao
S, Long D and Yu L: Association between platelet parameters and
mortality in coronavirus disease 2019: Retrospective cohort study.
Platelets. 31:490–496. 2020.PubMed/NCBI View Article : Google Scholar
|
